Report Description Table of Contents How Are HER2-Targeted Treatments, Immunotherapy Combinations, and Clinical Advances Shaping the HER2-Positive Gastric Cancer Market? – (Updated On: 19th-Nov-2026) According to Strategic Market Research, the Global HER2 Positive Gastric Cancer Market was valued at USD 1.47 billion in 2025 and is projected to reach USD 2.96 billion by 2032, growing at a CAGR of 10.5% during 2026–2032. Increasing treatment of advanced HER2-positive gastric cancer, wider biomarker testing, and adoption of targeted therapy and immunotherapy combinations are supporting market expansion. How Are HER2 Testing, Clinical Outcomes, and Treatment Adoption Influencing the Market? HER2-positive gastric cancer affects a significant number of stomach cancer patients worldwide. A 2026 review involving 19,903 patients found that approximately 16% of gastric cancer patients had HER2 overexpression. According to IARC, around 980,000 new stomach cancer cases and 642,000 deaths were recorded globally in 2024. In the United States, the American Cancer Society estimates 31,510 new cases and 10,740 deaths in 2026. These figures highlight the large number of stomach cancer patients who may need HER2 testing to determine whether targeted treatment is suitable. HER2 testing is particularly important for patients with advanced stomach cancer. A 2026 U.S. study involving 3,828 patients with advanced gastric or gastroesophageal junction cancer found that 57% were diagnosed with stage IV or IVB disease. Around 78% underwent HER2 testing, and 17% of those tested were HER2-positive. This means approximately 17 out of every 100 tested patients could be considered for HER2-targeted treatment, depending on their clinical eligibility. These findings show the importance of testing in identifying patients who may benefit from targeted medicines. Real-world U.S. evidence shows established use of HER2-directed treatment among eligible patients. A May 2026 study presented at ASCO reported that 62% of HER2-positive patients received HER2-directed therapy. This demonstrates existing treatment adoption while identifying further opportunity to improve access among eligible patients. New treatment combinations are helping patients with advanced HER2-positive gastric cancer live longer. In March 2025, the U.S. FDA approved pembrolizumab for use with trastuzumab and chemotherapy in certain HER2-positive gastric cancer patients. In a clinical trial involving 698 patients, those with PD-L1-positive tumors who received the pembrolizumab combination lived for a median of 20.1 months, compared with 15.7 months for those receiving trastuzumab and chemotherapy without pembrolizumab. Tumor shrinkage was also seen in 73% of patients receiving the pembrolizumab combination, compared with 58% in the comparison group. These results show the benefit of adding immunotherapy to existing HER2-targeted treatment. Trastuzumab deruxtecan is providing another treatment option for patients whose cancer worsens after earlier treatment. In the 2025 DESTINY-Gastric04 trial, involving 494 patients with advanced HER2-positive gastric or gastroesophageal junction cancer, patients receiving trastuzumab deruxtecan lived for a median of 14.7 months, compared with 11.4 months for those receiving ramucirumab and paclitaxel. The treatment also reduced tumor size in 44.3% of patients, compared with 29.1% receiving the other treatment. These results highlight the importance of newer HER2-targeted medicines for patients who need additional treatment. Hospitals in China are treating more HER2-positive gastric cancer patients with targeted medicines. A 2026 study of 805 patients across nine hospitals found that the proportion receiving HER2-targeted medicines as their first treatment increased from 60.83% in 2018 to 90.19% in 2023. During the same period, the use of HER2-targeted medicines together with immunotherapy rose from 0.83% to 60.78%. These findings show how HER2-targeted treatment has become more widely used in the hospitals studied, supporting demand for these medicines in China. Overall, the HER2 Positive Gastric Cancer Market is supported by established trastuzumab-based treatment, increasing use of pembrolizumab combinations, and growing clinical evidence for trastuzumab deruxtecan. Recent U.S. treatment data and Chinese hospital evidence show that biomarker-confirmed eligibility and adoption of HER2-directed therapies remain central to market demand through 2032. Which Treatment Types Are Contributing Most to HER2-Positive Gastric Cancer Market Revenue? Targeted Therapy — Largest Treatment Category Targeted therapy accounts for an estimated 41% of global market revenue, equivalent to USD 0.603 billion in 2025, and is projected to grow at a CAGR of 10.10% during 2026–2032. It is the leading treatment category for patients with HER2-positive advanced gastric and gastroesophageal junction (GEJ) cancer.Trastuzumab remains an established first-line HER2-directed treatment, while trastuzumab deruxtecan provides an option after previous trastuzumab-based therapy. In the ToGA trial, trastuzumab plus chemotherapy achieved median overall survival of 13.8 months, compared with 11.1 months for chemotherapy alone. These established treatments support the segment's commercial position. Immunotherapy — Fastest-Growing Treatment Category Immunotherapy represents an estimated 17% of global market revenue, generating USD 0.250 billion in 2025, and is projected to register the fastest CAGR of 13.80% during 2026–2032. Its opportunity is concentrated in HER2-positive advanced gastric cancer patients who are eligible for immune checkpoint inhibitor combinations.Merck's pembrolizumab, combined with trastuzumab and chemotherapy, is an FDA-approved first-line treatment for eligible patients with PD-L1 CPS ≥1. The KEYNOTE-811 trial demonstrated improved clinical outcomes with this combination, strengthening immunotherapy's role in first-line treatment. Which Treatment Lines Are Generating the Highest Revenue in HER2-Positive Gastric Cancer Care? First-Line Treatment — Largest Treatment-Line Category First-line treatment accounts for an estimated 61% of global market revenue, equivalent to USD 0.897 billion in 2025, and is projected to expand at a CAGR of 10.00% during 2026–2032. Its leading position reflects the use of HER2-targeted medicines alongside chemotherapy and immunotherapy in eligible patients with advanced or metastatic disease.Trastuzumab-based treatment remains central to first-line care, while pembrolizumab-containing combinations provide additional options for PD-L1-positive patients. This stage represents a major commercial opportunity because it includes patients beginning systemic treatment for advanced disease. Second-Line Treatment — Fastest-Growing Treatment-Line Category Second-line treatment represents an estimated 27% of global market revenue, equivalent to USD 0.397 billion in 2025, and is projected to grow at the fastest CAGR of 11.40% during 2026–2032. Its expansion reflects the need for additional treatment following disease progression after first-line therapy.Daiichi Sankyo and AstraZeneca's Enhertu is an important HER2-directed option for previously treated patients. The DESTINY-Gastric01 trial reported an objective response rate of approximately 51% with trastuzumab deruxtecan, compared with 14% for physician-selected chemotherapy. Such clinical evidence supports continued interest in subsequent-line treatments. Which Cancer Stages Account for the Largest Treatment Opportunities? Metastatic Gastric Cancer — Largest Cancer-Stage Category Metastatic gastric cancer represents an estimated 62% of global market revenue, equivalent to USD 0.911 billion in 2025, and is projected to expand at a CAGR of 10.40% during 2026–2032. Its revenue leadership reflects the established use of systemic HER2-directed therapies in patients whose disease has spread beyond the stomach.Trastuzumab-containing regimens and subsequent-line HER2-directed treatments are important in metastatic disease management. HER2 testing determines eligibility for targeted therapy, while PD-L1 assessment helps identify patients suitable for selected immunotherapy combinations. Recurrent Gastric Cancer — Fastest-Growing Cancer-Stage Category Recurrent gastric cancer accounts for an estimated 14% of global market revenue, generating USD 0.206 billion in 2025, and is projected to record the fastest CAGR of 12.16% during 2026–2032. Treatment opportunities arise when cancer returns following initial therapy and requires additional clinical intervention.Repeat biomarker assessment may help identify changes in HER2 expression, particularly after previous targeted treatment. Availability of antibody-drug conjugates and continuing research into later-line combinations could provide additional options for eligible patients experiencing recurrence. Which Healthcare Settings Are Contributing Most to HER2-Positive Gastric Cancer Treatment Revenue? Hospitals — Largest End-User Category Hospitals account for an estimated 67% of global market revenue, equivalent to USD 0.985 billion in 2025, and are projected to grow at a CAGR of 9.70% during 2026–2032. Their leading position is supported by the concentration of advanced gastric cancer treatment, HER2 biomarker testing, and systemic oncology services.Hospitals provide multidisciplinary cancer management, including targeted drug administration, chemotherapy, disease monitoring, and treatment of complications. Their role is particularly important for patients with advanced disease who require coordinated oncology care. Specialty Oncology Centers — Fastest-Growing End-User Category Specialty oncology centers represent an estimated 27% of global market revenue, generating USD 0.397 billion in 2025, and are projected to record the fastest CAGR of 12.20% during 2026–2032. These facilities provide dedicated cancer treatment services for patients receiving HER2-directed medicines and combination regimens. Their commercial opportunity is supported by outpatient infusion services, biomarker-guided treatment, and ongoing patient monitoring. Continued adoption of targeted therapies and immunotherapy combinations is expected to strengthen their role in gastric cancer care. Which Countries Are Shaping the HER2-Positive Gastric Cancer Market? United States — Largest Country Market The United States accounts for an estimated 30% of global market revenue, equivalent to USD 0.441 billion in 2025, and is projected to grow at an indicative CAGR of 10.20% during 2026–2032. Its revenue position is supported by established oncology services, access to biomarker testing, and availability of FDA-approved HER2-directed treatments. The American Cancer Society estimated approximately 30,300 new stomach cancer cases in the United States in 2025. Although HER2-positive patients represent only a proportion of this population, the availability of trastuzumab, pembrolizumab combinations, and trastuzumab deruxtecan supports a substantial market for advanced gastric cancer treatment. Higher innovative drug prices and insurance reimbursement also influence U.S. treatment revenue. India — Fastest-Growing Country India accounts for an estimated 3% of global market revenue, equivalent to USD 0.044 billion in 2025, and is projected to register an indicative CAGR of 15.00% during 2026–2032. Its market opportunity is associated with expanding specialized oncology services, greater availability of HER2 testing, and access to trastuzumab biosimilars. According to IARC GLOBOCAN 2022 estimates, India recorded approximately 64,600 new stomach cancer cases, indicating a considerable underlying patient population. Applying the broad 15–20% HER2-positivity range suggests approximately 9,700–12,900 potentially HER2-positive cases, although this is an illustrative calculation rather than a published national HER2-positive case count. Testing availability, stage at diagnosis, treatment affordability, and insurance coverage will determine how much of this population receives HER2-directed treatment. Which FDA-Approved and Emerging Therapies Are Reshaping HER2-Positive Gastric Cancer Treatment? Trastuzumab (Herceptin) and Biosimilars — Established First-Line HER2-Targeted Treatment Roche's Herceptin (trastuzumab) is an established HER2-directed therapy approved by the FDA for first-line treatment of metastatic HER2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma in combination with specified chemotherapy regimens. The pivotal ToGA trial demonstrated median overall survival of 13.8 months with trastuzumab plus chemotherapy, compared with 11.1 months with chemotherapy alone. FDA-approved trastuzumab biosimilars, including trastuzumab-dkst, are increasing competition and providing more affordable treatment options, particularly for oncology providers managing treatment costs. Pembrolizumab (Keytruda) — Advancing First-Line Immunotherapy Combinations Merck's Keytruda (pembrolizumab) is FDA-approved in combination with trastuzumab and chemotherapy for first-line treatment of locally advanced unresectable or metastatic HER2-positive gastric or GEJ adenocarcinoma in patients with PD-L1 CPS ≥1. The Phase III KEYNOTE-811 trial demonstrated improved clinical outcomes with pembrolizumab-containing combinations. Its commercial importance lies in expanding the use of immunotherapy alongside established HER2-targeted treatment, creating additional opportunities for manufacturers serving biomarker-selected oncology populations. Fam-Trastuzumab Deruxtecan-nxki (Enhertu) — Expanding Subsequent-Line Treatment Enhertu, developed by Daiichi Sankyo and AstraZeneca, is an FDA-approved HER2-directed antibody-drug conjugate for patients with locally advanced or metastatic HER2-positive gastric or GEJ adenocarcinoma previously treated with trastuzumab-based therapy. In the DESTINY-Gastric01 trial, Enhertu achieved an objective response rate of approximately 51%, compared with 14% for physician-selected chemotherapy. Median overall survival reached 12.5 months versus 8.4 months. These outcomes support its position in previously treated disease and strengthen commercial opportunities for antibody-drug conjugates, although pulmonary toxicity requires careful monitoring. Zanidatamab-hrii (Ziihera) — Emerging Bispecific HER2-Directed Treatment Ziihera (zanidatamab-hrii) is a bispecific HER2-directed antibody being investigated in HER2-positive gastric and GEJ adenocarcinoma, including combinations with chemotherapy and immunotherapy. The FDA granted zanidatamab accelerated approval in November 2024 for previously treated HER2-positive biliary tract cancer, rather than gastric cancer under that original indication. Its gastric cancer development represents a potential competitive opportunity, but any subsequent gastric-specific FDA authorization requires confirmation against current regulatory records. Further clinical evidence and regulatory decisions will determine its commercial position alongside trastuzumab-based combinations and antibody-drug conjugates. Which Pharmaceutical Companies Are Competing in the Global HER2-Positive Gastric Cancer Market? Roche — Established HER2-Targeted Treatment Portfolio Roche maintains an important position through Herceptin (trastuzumab), an established first-line HER2-directed treatment for metastatic gastric and gastroesophageal junction cancer. The pivotal ToGA trial reported median overall survival of 13.8 months with trastuzumab plus chemotherapy, compared with 11.1 months with chemotherapy alone. Roche's commercial position is supported by established clinical use of trastuzumab and its HER2 diagnostic capabilities. However, growing competition from trastuzumab biosimilars is creating pricing pressure, particularly in healthcare systems seeking more affordable targeted treatments. Merck & Co. — First-Line Immunotherapy Combinations Merck competes through Keytruda (pembrolizumab), an FDA-approved immunotherapy used with trastuzumab and chemotherapy for eligible patients with HER2-positive, PD-L1-positive advanced gastric or GEJ cancer. The KEYNOTE-811 trial reported an objective response rate of approximately 73% with pembrolizumab-containing treatment, compared with 58% in the control group in an earlier analysis. Merck's commercial opportunity is linked to wider use of biomarker-guided immunotherapy combinations and access to advanced oncology treatment. Daiichi Sankyo — HER2-Directed Antibody-Drug Conjugates Daiichi Sankyo is a major participant through Enhertu (trastuzumab deruxtecan), developed and commercialized with AstraZeneca. The treatment is FDA-approved for eligible patients with locally advanced or metastatic HER2-positive gastric or GEJ cancer following previous trastuzumab-based therapy. The DESTINY-Gastric01 trial demonstrated an objective response rate of approximately 51% with Enhertu, compared with 14% for physician-selected chemotherapy. Its commercial position reflects the importance of subsequent-line targeted treatment and continued clinical development of antibody-drug conjugates. Other Relevant Pharmaceutical Companies: AstraZeneca: Co-develops and commercializes Enhertu with Daiichi Sankyo, supporting global access and clinical development of HER2-directed antibody-drug conjugates. Pfizer: Supplies Trazimera, a trastuzumab biosimilar, contributing to competition and potentially improving affordability of established HER2-targeted therapy. How Was the HER2-Positive Gastric Cancer Market Assessed? The market assessment covers HER2-directed targeted therapies, chemotherapy, immunotherapy, and combination treatments used for HER2-positive gastric and gastroesophageal junction adenocarcinoma, with particular emphasis on advanced and metastatic disease. The assessment considers gastric cancer incidence, HER2 positivity rates of approximately 15–20%, biomarker testing, treatment eligibility, first-line and subsequent-line therapy utilization, and geographic differences in access to oncology medicines. The historical period is 2019–2024, the base year is 2025, and the forecast period is 2026–2032. According to Strategic Market Research, the global market was valued at USD 1.47 billion in 2025 and is projected to reach USD 2.96 billion by 2032, at a CAGR of 10.5%. The market valuation and segment-level estimates represent Strategic Market Research assumptions. HER2-positive incidence does not directly represent the treated population, as treatment eligibility depends on cancer stage, biomarker confirmation, clinical condition, and access to therapy. Revenue from combination regimens must also be allocated carefully to prevent double counting across treatment categories. Segment estimates require further validation against medicine utilization, treatment prices, and national oncology expenditure before external publication. Analyst Commentary: How Will Treatment Innovation and Biosimilar Competition Influence Market Opportunities? The HER2-positive gastric cancer market offers substantial commercial opportunities in first-line immunotherapy combinations, next-generation antibody-drug conjugates, and biomarker-guided oncology. Manufacturers demonstrating improved survival outcomes and securing broader treatment access are positioned to capture higher-value pharmaceutical revenue. Biosimilar competition, reimbursement restrictions, and unequal access to innovative therapies will remain important factors influencing market performance through 2032. HER2 Positive Gastric Cancer Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 1.47 Billion Revenue Forecast in 2032 USD 2.96 Billion Overall Growth Rate CAGR of 10.5% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Million/Billion, CAGR (2026 – 2032) Segmentation By Treatment Type, By Treatment Line, By Cancer Stage, By End User, By Geography By Treatment Type Targeted Therapy, Chemotherapy, Immunotherapy, Combination Therapy By Treatment Line First-Line Treatment, Second-Line Treatment, Third-Line and Later-Line Treatment By Cancer Stage Metastatic Gastric Cancer, Locally Advanced Gastric Cancer, Recurrent Gastric Cancer By End User Hospitals, Specialty Oncology Centers, Cancer Research Institutes By Region North America, Europe, Asia-Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Wider HER2 biomarker testing, treatment of advanced HER2-positive gastric cancer, adoption of HER2-targeted therapies, use of targeted therapy and immunotherapy combinations, improved treatment access among eligible patients Customization Option Available upon request Frequently Asked Question About This Report Q1. How is HER2 biomarker testing influencing treatment adoption in the market? A1. HER2 testing helps identify gastric cancer patients eligible for targeted treatment. A 2026 U.S. study involving 3,828 patients found that 78% underwent HER2 testing, with 17% testing positive. Wider testing can increase the number of eligible patients identified for trastuzumab-based therapies and immunotherapy combinations. Q2. What are the latest clinical advancements transforming the industry? A2. Pembrolizumab combinations and trastuzumab deruxtecan are improving treatment outcomes. The KEYNOTE-811 trial reported median overall survival of 20.1 months with pembrolizumab-based treatment compared with 15.7 months in the control group. The DESTINY-Gastric04 trial also demonstrated improved survival with trastuzumab deruxtecan in previously treated patients. Q3. Which treatment category is expected to grow fastest in the market? A3. Immunotherapy is projected to record the fastest treatment-category CAGR of 13.8% through 2032. Its estimated revenue was USD 250 million in 2025. Growing adoption of pembrolizumab alongside trastuzumab and chemotherapy in eligible HER2-positive patients supports this expansion. Q4. How is demand evolving across different regions of the industry? A4. Asia-Pacific leads with an estimated 37% revenue share in 2025 and is projected to grow at a CAGR of 11.4% through 2032. China, Japan, and South Korea contribute through substantial gastric cancer treatment demand. India is expected to record faster country-level growth at approximately 15%, supported by expanding HER2 testing and access to targeted therapies. Q5. What strategies are pharmaceutical companies adopting to strengthen their market position? A5. Companies are developing combination therapies and expanding access to HER2-directed medicines. Merck competes through Keytruda-based first-line regimens, while Daiichi Sankyo and AstraZeneca offer Enhertu for previously treated patients. Roche maintains its position through Herceptin, although trastuzumab biosimilars are increasing competition. Q6. What are the major opportunities available in the industry? A6. First-line immunotherapy combinations and subsequent-line antibody-drug conjugates offer important revenue opportunities. First-line treatment accounted for 61% of market revenue in 2025, while second-line treatment is projected to grow fastest at a CAGR of 11.4%. Wider biomarker testing could also increase access to targeted medicines among eligible patients. Sources: U.S. FDA – Approved Zanidatamab-Based First-Line Regimens for HER2-Positive Advanced Gastric and Related Cancers on August 25, 2026 FDA – Ziihera With Chemotherapy, With or Without Tislelizumab: Approved Indications and HER2 Eligibility Jazz Pharmaceuticals – August 2026 Results Reported Median Overall Survival of 26.4 Months With Zanidatamab, Tislelizumab, and Chemotherapy Versus 19.2 Months With Trastuzumab and Chemotherapy Jazz Pharmaceuticals – HERIZON-GEA-01 Results and U.S. Approval of Ziihera-Based First-Line Treatment Roche – Announced Expanded FDA Approval of Two HER2 Companion Diagnostic Tests for Identifying Patients Eligible for Ziihera on August 27, 2026 Roche – PATHWAY HER2 and VENTANA HER2 Dual ISH Tests for Metastatic Gastroesophageal Adenocarcinoma U.S. FDA – Granted Traditional Approval to Pembrolizumab With Trastuzumab and Chemotherapy for HER2-Positive Gastric or GEJ Cancer With PD-L1 CPS ≥1 on March 19, 2025 FDA – KEYNOTE-811: Median Overall Survival of 20.1 Versus 15.7 Months and Response Rates of 73% Versus 58% in the PD-L1-Positive Population Daiichi Sankyo – May 2025 DESTINY-Gastric04 Results Showed Median Overall Survival of 14.7 Months With Enhertu Versus 11.4 Months With Ramucirumab and Paclitaxel Across 494 Patients Daiichi Sankyo – Enhertu Reduced the Risk of Death by 30% in Previously Treated HER2-Positive Advanced Gastric Cancer AstraZeneca – Reported in a 2026 Company Update That Enhertu Was Approved in More Than 90 Countries and Regions for HER2-Positive Advanced Gastric or GEJ Cancer Following Prior Trastuzumab-Based Treatment AstraZeneca – Enhertu Regulatory Update and Gastric Cancer Approval Footprint U.S. National Cancer Institute – Reports Estimated U.S. Stomach Cancer Incidence of 31,510 New Cases and 10,740 Deaths in 2026; These Figures Cover All Stomach Cancers NCI SEER – Stomach Cancer: 2026 Incidence and Mortality Estimates Table of Contents - Global HER2-Positive Gastric Cancer Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Treatment Type, Treatment Line, Cancer Stage, End User, and Region Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Treatment Type, Treatment Line, Cancer Stage, End User, and Region Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Treatment Type, Treatment Line, Cancer Stage, and End User Investment Opportunities in the HER2-Positive Gastric Cancer Market Key Developments and Innovations in HER2-Targeted Treatments Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Trastuzumab-Based Treatment, Immunotherapy Combinations, Antibody-Drug Conjugates, HER2 Biosimilars, and Biomarker Testing Emerging Opportunities in First-Line and Subsequent-Line Treatment Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets HER2-Positive Gastric and Gastroesophageal Junction Cancer Overview Strategic Importance of HER2 Biomarker Testing and Targeted Oncology Treatment Role of Immunotherapy Combinations and Antibody-Drug Conjugates in Advanced Gastric Cancer Management Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach HER2-Positive Patient Population and Treatment Eligibility Assessment Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Regulatory Approvals and Oncology Treatment Guidelines Role of HER2 Biomarker Testing in Identifying Eligible Patients Impact of Trastuzumab-Based Treatment and Pembrolizumab Combinations on Market Expansion Adoption of Trastuzumab Deruxtecan and Other Antibody-Drug Conjugates Influence of Biosimilar Competition, Treatment Affordability, and Reimbursement Access Clinical Outcomes, Treatment-Line Expansion, and Regional Oncology Access Trends Global HER2-Positive Gastric Cancer Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type: Targeted Therapy Chemotherapy Immunotherapy Combination Therapy Market Analysis by Treatment Line: First-Line Treatment Second-Line Treatment Third-Line and Later-Line Treatment Market Analysis by Cancer Stage: Metastatic Gastric Cancer Locally Advanced Gastric Cancer Recurrent Gastric Cancer Market Analysis by End User: Hospitals Specialty Oncology Centers Cancer Research Institutes Market Analysis by Region: North America Europe Asia-Pacific Latin America Middle East & Africa Regional Market Analysis North America HER2-Positive Gastric Cancer Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Treatment Line, Cancer Stage, and End User HER2 Biomarker Testing and FDA-Approved Treatment Adoption Country-Level Breakdown: United States Canada Mexico Europe HER2-Positive Gastric Cancer Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Treatment Line, Cancer Stage, and End User Access to HER2-Targeted Therapies and Advanced Oncology Treatments Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia-Pacific HER2-Positive Gastric Cancer Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Treatment Line, Cancer Stage, and End User Gastric Cancer Burden, HER2 Testing, and Targeted Treatment Adoption Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia-Pacific Latin America HER2-Positive Gastric Cancer Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Treatment Line, Cancer Stage, and End User HER2 Diagnostic Access and Targeted Oncology Treatment Availability Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East & Africa HER2-Positive Gastric Cancer Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Treatment Type, Treatment Line, Cancer Stage, and End User Specialized Oncology Services and Access to HER2-Targeted Medicines Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: Roche Merck & Co. Daiichi Sankyo AstraZeneca Pfizer Inc. Bristol Myers Squibb Eli Lilly and Company Amgen Inc. BeiGene Samsung Bioepis Celltrion Gilead Sciences Seagen MacroGenics Competitive Landscape and Strategic Insights Benchmarking Based on HER2-Targeted Treatment Portfolios, Clinical Outcomes, Biomarker Testing, and Regional Presence Trastuzumab and Biosimilar Portfolio Positioning Pembrolizumab Combination Treatment Competitiveness Trastuzumab Deruxtecan and Antibody-Drug Conjugate Development First-Line and Subsequent-Line Treatment Strategy Analysis Clinical Trial Development and Regulatory Approval Assessment Appendix Abbreviations and Terminologies Used in the Report References and Sources HER2 Biomarker Testing and Treatment Eligibility Definitions Clinical Trial and Regulatory Information List of Tables Market Size by Treatment Type, Treatment Line, Cancer Stage, End User, and Region (2026–2032) Historical Market Size and Volume (2019–2024), Base Year Market Size Analysis (2025), and Market Forecasts (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Country-Level Market Analysis Across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa Competitive Benchmarking of Leading Pharmaceutical Companies HER2-Targeted Therapy and Immunotherapy Combination Analysis Clinical Trial Outcomes and Treatment-Line Adoption Analysis Biomarker Testing, Regulatory Approvals, and Treatment Access Analysis List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Treatment Type, Treatment Line, Cancer Stage, and End User (2025 vs. 2032) Global HER2-Positive Gastric Cancer Ecosystem and Value Chain Analysis HER2-Targeted Treatment and Immunotherapy Combination Landscape Regional Adoption of HER2 Biomarker Testing and Targeted Therapies